These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 38465573)

  • 1. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.
    Allen AM; Charlton M; Cusi K; Harrison SA; Kowdley KV; Noureddin M; Shubrook JH
    Postgrad Med; 2024 Apr; 136(3):229-245. PubMed ID: 38465573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Jun; ():. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deploying a metabolic dysfunction-associated steatohepatitis consensus care pathway: findings from an educational pilot in three health systems.
    Kumar S; Mohanty A; Mantry P; Schwartz RE; Haff M; Therapondos G; Noureddin M; Dieterich D; Girgrah N; Cohn K; Savanth M; Fuchs M
    BMC Prim Care; 2024 Jul; 25(1):265. PubMed ID: 39033284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ; ;
    J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypes of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatocellular Carcinoma.
    Rivera-Esteban J; Muñoz-Martínez S; Higuera M; Sena E; Bermúdez-Ramos M; Bañares J; Martínez-Gomez M; Cusidó MS; Jiménez-Masip A; Francque SM; Tacke F; Minguez B; Pericàs JM
    Clin Gastroenterol Hepatol; 2024 Sep; 22(9):1774-1789.e8. PubMed ID: 38604295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.
    Marti-Aguado D; Calleja JL; Vilar-Gomez E; Iruzubieta P; Rodríguez-Duque JC; Del Barrio M; Puchades L; Rivera-Esteban J; Perelló C; Puente A; Gomez-Medina C; Escudero-García D; Serra MA; Bataller R; Crespo J; Arias-Loste MT
    J Hepatol; 2024 Jul; ():. PubMed ID: 38971533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies.
    Kokkorakis M; Muzurović E; Volčanšek Š; Chakhtoura M; Hill MA; Mikhailidis DP; Mantzoros CS
    Pharmacol Rev; 2024 May; 76(3):454-499. PubMed ID: 38697855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting.
    Gupta U; Ruli T; Buttar D; Shoreibah M; Gray M
    Am J Med Sci; 2024 Feb; 367(2):77-88. PubMed ID: 37967750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex-based differences in natural killer T cell-mediated protection against diet-induced steatohepatitis in Balb/c mice.
    Cuño-Gómiz C; de Gregorio E; Tutusaus A; Rider P; Andrés-Sánchez N; Colell A; Morales A; Marí M
    Biol Sex Differ; 2023 Nov; 14(1):85. PubMed ID: 37964320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
    Li C; Wang T; Song J
    Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
    Armandi A; Bugianesi E
    Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
    Zeng J; Fan JG; Francque SM
    United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small intestinal bacterial overgrowth in obese patients with biopsy-confirmed metabolic dysfunction-associated steatotic liver disease: a cross-sectional study.
    Ortiz-López N; Madrid AM; Aleman L; Zazueta A; Smok G; Valenzuela-Pérez L; Poniachik J; Beltrán CJ
    Front Med (Lausanne); 2024; 11():1376148. PubMed ID: 38854668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis.
    Tincopa MA; Loomba R
    Semin Liver Dis; 2024 Jul; ():. PubMed ID: 38981691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we ready for genetic testing in metabolic dysfunction-associated steatotic liver disease?
    Tulone A; Pennisi G; Ciccioli C; Infantino G; La Mantia C; Cannella R; Mercurio F; Petta S
    United European Gastroenterol J; 2024 Jun; 12(5):638-648. PubMed ID: 38659291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.
    Noureddin N; Copur-Dahi N; Loomba R
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1(Suppl 1):S41-S51. PubMed ID: 38813822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes.
    Godoy-Matos AF; Valério CM; Silva Júnior WS; de Araujo-Neto JM; Bertoluci MC
    Diabetol Metab Syndr; 2024 Jan; 16(1):23. PubMed ID: 38238868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
    Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
    Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.